347 related articles for article (PubMed ID: 33211395)
1. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
Wang H; Zhao Y; Zhang X; Si X; Song P; Xiao Y; Yang X; Song L; Shi J; Zhao H; Zhang L
Cancer Med; 2021 Jan; 10(1):188-198. PubMed ID: 33211395
[TBL] [Abstract][Full Text] [Related]
2. [Clinical and chest CT features of immune checkpoint inhibitor-related pneumonitis].
Zhang Q; Zhao SJ; Wang SH; Tao XL; Wu N
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):182-187. PubMed ID: 36781241
[No Abstract] [Full Text] [Related]
3. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.
Lin X; Lu T; Li S; Xie X; Chen X; Jiang J; Qin Y; Xie Z; Liu M; Ouyang M; Zhong N; Song Y; Zhou C
Clin Transl Oncol; 2021 Feb; 23(2):389-396. PubMed ID: 32613413
[TBL] [Abstract][Full Text] [Related]
4. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics, Management and Prognostic Factors of Immune Checkpoint Inhibitor-Associated Pneumonia in Chinese Cancer Patients.
Li J; Chen S; Yan T; Zeng M
J Coll Physicians Surg Pak; 2024 Mar; 34(3):302-307. PubMed ID: 38462865
[TBL] [Abstract][Full Text] [Related]
6. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
[TBL] [Abstract][Full Text] [Related]
7. [Clinical features and prognostic analysis of checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer].
Chen RX; Liu XN; Xu Y; Shi YJ; Wang MQ; Shao C; Huang H; Xu K; Wang MZ; Xu ZJ
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Mar; 47(3):207-213. PubMed ID: 38448169
[No Abstract] [Full Text] [Related]
8. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.
Tiu BC; Zubiri L; Iheke J; Pahalyants V; Theodosakis N; Ugwu-Dike P; Seo J; Tang K; Sise ME; Sullivan R; Naidoo J; Mooradian MJ; Semenov YR; Reynolds KL
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705313
[TBL] [Abstract][Full Text] [Related]
9. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
[TBL] [Abstract][Full Text] [Related]
10. Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis.
Park C; Keam B; Yoon SH; Ock CY; Choi SM; Kim M; Park YS; Kim TM; Oh DY; Kim DW; Kim YW; Heo DS; Bang YJ
ESMO Open; 2019; 4(6):e000575. PubMed ID: 31803501
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Pang L; Xie M; Ma X; Huang A; Song J; Yao J; Deng H; Zhang D; Zang X; Ren F; Gao J; Wu C; Wang Y; Zhang X; Bao X; Pan L; Xue X
BMC Cancer; 2023 Mar; 23(1):203. PubMed ID: 36869304
[TBL] [Abstract][Full Text] [Related]
12. Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer.
Tao H; Li F; Wu D; Ji S; Liu Q; Wang L; Liu B; Facchinetti F; Leong TL; Passiglia F; Hu Y
Transl Lung Cancer Res; 2022 Mar; 11(3):381-392. PubMed ID: 35399572
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L
Front Immunol; 2022; 13():918787. PubMed ID: 35795657
[TBL] [Abstract][Full Text] [Related]
15. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors.
Shibata Y; Murakami S; Kato T
Expert Opin Drug Saf; 2021 May; 20(5):537-547. PubMed ID: 33650443
[No Abstract] [Full Text] [Related]
16. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
Zhou P; Zhao X; Wang G
Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
[TBL] [Abstract][Full Text] [Related]
17. [A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1
Antibody-Safety and Effectiveness of Pirfenidone].
Yu H; Li J; Yu L; Cheng X; Han X; Zhang X
Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):519-525. PubMed ID: 34134189
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
Atchley WT; Alvarez C; Saxena-Beem S; Schwartz TA; Ishizawar RC; Patel KP; Rivera MP
Chest; 2021 Aug; 160(2):731-742. PubMed ID: 33621599
[TBL] [Abstract][Full Text] [Related]
19. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
20. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
[No Abstract] [Full Text] [Related]
[Next] [New Search]
